Latest News for: nk cells

Edit

Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and ...

Nasdaq Globe Newswire 07 Apr 2025
Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases. Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases ... .
Edit

Biohacker Bryan Johnson's anti ageing drug just might have accelerated his ageing: 'Irony hunts me'

The Times of India 07 Apr 2025
Johnson’s radical pursuit of longevity has made headlines quite a few times ... rapamycin ... Bryan didn’t just read this in studies; he felt it in his body.More alarmingly, the drug also suppresses NK cells, which help fight cancer.
Edit

Future Trends in The Cell and Gene Therapy Market: Forecast Until 2035

Pharmiweb 04 Apr 2025
Cell And Gene Therapy Market Size and Forecast. The global cell and gene therapy market is projected to witness significant growth in the coming years ... By Therapy Type Cell Therapy Stem Cells T Cells Dendritic Cells NK Cells Tumor Cells Gene Therapy.
Edit

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

GetNews 02 Apr 2025
ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space ... FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers.
Edit

Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, ...

GetNews 28 Mar 2025
... Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics/Pharmacokinetics, and Antitumor Activity of GNC-038 Injection in Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL.
Edit

B-Cell Lymphoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 24 Mar 2025
Stay ahead with the most recent pipeline outlook for B-Cell Lymphoma ... Its primary goal is to enhance the immune system's capacity to combat cancer by boosting the proliferation and survival of natural killer (NK) cells and memory CD8+ T cells.
Edit

Bharat Biotech forays into cell and gene therapy with $75 million vertically integrated CGT, viral production facility at Genome Valley

The Times of India 20 Mar 2025
We already have a pipeline of five products that we are working on with therapies such as CAR-T cell, CAR-NK cell as well as off-the-shelf gene therapies,” Raches Ella said.“Our established expertise ...
Edit

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy

ACCESSWIRE 18 Mar 2025
APVO603 is a novel bispecific antibody designed to enhance anti-tumor immune responses through dual targeting of 4-1BB (CD137) and OX40 (CD134), two key co-stimulatory receptors involved in T cell and NK cell activation.
Edit

Stem Cell Stocks on the Rise: Companies Driving the $48 Billion Market Boom

GetNews 18 Mar 2025
The company’s proprietary platform creates engineered iPSC lines for off-the-shelf T-cell and NK-cell products, targeting diseases in autoimmunity and oncology ... The company’s FT522 CAR NK ...
Edit

NK Cell Therapy Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, IND, NDA Approval, ...

GetNews 17 Mar 2025
NK Cell Therapy Report Metrics Details Study Period 2020–2034 NK Cell Therapy Report Coverage 7MM Key NK Cell Therapy Companies Artiva Biotherapeutics, Glycostem, Fate Therapeutics, Indapta ...
Edit

Coeptis (NASDAQ: COEP) Accelerates Growth with Strategic Partnerships and Innovation

GetNews 17 Mar 2025
(NasdaQ ... Exclusive License to GEARCell Therapy. A breakthrough approach in cancer treatment leveraging genetically modified natural killer (NK) cells to enhance deep remission in patients with hematologic malignancies and solid tumors ... (NYSE.
  • 1
×